New drug OMO-103 studied in pancreatic cancer patients to reveal tumor changes
NCT ID NCT07089940
First seen Mar 25, 2026 · Last updated May 16, 2026 · Updated 5 times
Summary
This early phase 1 trial is studying how the drug OMO-103 affects pancreatic cancer cells in 12 patients with advanced or metastatic disease. The main goal is to see if the drug causes measurable changes in the tumor's biology by comparing tissue samples taken before and after treatment. Researchers also track side effects. This study is not designed to cure or control the disease, but to gather important information about how the drug works in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
RECRUITINGPortland, Oregon, 97239, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.